ResMed Inc. (NASDAQ:RMD) reported its results for the third quarter. ResMed Inc. is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
ResMed Earnings Cheat Sheet for the Third Quarter
Results: Net income for ResMed Inc. rose to $53.4 million (34 cents/share) vs. $48.8 million (32 cents/share) in the same quarter a year earlier. A rise of 9.2% from the year earlier quarter.
Revenue: Rose 12.4% to $313.3 million YoY.
Actual vs. Wall St. Expectations: RMD fell short of the mean analyst estimate of 35 cents/share. Estimates ranged from 30 cents per share to 38 cents per share.
Quoting Management: Peter C. Farrell PhD, Chairman and Chief Executive Officer, commented, “In the third quarter of fiscal 2011 we continued to show strong year-over-year growth especially in Europe and the Asia-Pacific region. Revenue outside the Americas increased by 16% to $152.7 million over the prior year’s quarter, or a 15% increase on a constant currency basis. Revenue in the Americas increased by over 9% to $160.5 million over the prior year’s quarter.”
Key Stats: The company has enjoyed double-digit year-over-year revenue growth for the past five quarters. Over that span, the company has averaged growth of 15.2%, with the biggest boost coming in the third quarter of the last fiscal year when revenue rose 22.3% from the year earlier quarter.
The company has now seen net income rise in three-straight quarters. In the second quarter, net income rose 27.1% and in the first quarter, the figure rose 34.7%.
Competitors to Watch: Allied Healthcare Product (NASDAQ:AHPI), Masimo Corporation (NASDAQ:MASI), Electromed, Inc. (NASDAQ:ELMD), Medtronic, Inc. (NYSE:MDT), Dynatronics Corporation (NASDAQ:DYNT), Thermo Fisher Scientific Inc. (NYSE:TMO), Covidien plc (NYSE:COV), Dehaier Medical Systems Ltd (NASDAQ:DHRM), and CareFusion Corporation (NYSE:CFN).
Today’s Performance: Shares of RMD are unchanged in after hours trading.